Related Experiment Videos
Role of mizoribine in renal transplantation
1Department of Pediatrics, Chukyo Hospital, Nagoya, Japan.
Abstract:
Renal transplantation is the optimal form of therapy for children and adolescents with end-stage renal disease. Usually histocompatibility differences exist between donor and recipient, so it is necessary to modify or suppress the immune response to enable the recipient to accept a graft. Calcineurin inhibitors (CNI), which include cyclosporin (CsA) and tacrolimus (FK506), give many benefits on the outcome after renal transplantation, but have some toxic effects, especially nephrotoxicity. Therefore, inhibitors of purine synthesis revived as newer generation of more specific inhibitors, mizoribine (MZ) and mycophenolate mofetil (MMF). The Japanese pediatric renal transplantation clinical study group attempted to reduce and then discontinue steroid administration in combination with another three immunosuppressive drugs, CsA, MZ and anti-lymphocyte globulin (ALG). This study showed good clinical results. Mizoribine is an effective immunosuppressive drug in human renal transplantation. However, it is not as popular as other inhibitors of purine synthesis, such as azathioprine (AZA) and MMF, because MZ has been used mainly in Japan and infrequently in other countries. However, MZ is a more useful immunosuppressive drug than AZA, when it is used in combination with CNI.
Insights
Mizoribine (MZ) is an effective immunosuppressant for pediatric renal transplantation, especially when combined with calcineurin inhibitors (CNI). This study demonstrated good clinical outcomes by reducing steroid use with CsA, MZ, and anti-lymphocyte globulin (ALG).
Area of Science:
- Immunology
- Nephrology
- Pharmacology
Background:
- Renal transplantation is the preferred treatment for end-stage renal disease in pediatric patients.
- Immunosuppression is crucial to prevent graft rejection due to donor-recipient histocompatibility differences.
- Calcineurin inhibitors (CNI) like cyclosporin (CsA) and tacrolimus (FK506) are effective but can cause nephrotoxicity.
Purpose of the Study:
- To evaluate the efficacy and safety of mizoribine (MZ) in pediatric renal transplantation.
- To assess the potential for reducing or discontinuing steroid administration in immunosuppressive regimens.
- To compare MZ with other purine synthesis inhibitors like azathioprine (AZA) and mycophenolate mofetil (MMF).
Main Methods:
- A Japanese pediatric renal transplantation clinical study was conducted.
- The regimen included CsA, MZ, and anti-lymphocyte globulin (ALG) with a strategy to reduce/discontinue steroids.
- Clinical outcomes were monitored to assess efficacy and safety.
Main Results:
- The combination therapy of CsA, MZ, and ALG, with reduced steroid use, yielded good clinical results.
- Mizoribine (MZ) demonstrated effectiveness as an immunosuppressive agent in human renal transplantation.
- MZ showed greater utility than AZA when used concurrently with CNI.
Conclusions:
- Mizoribine (MZ) is a valuable immunosuppressive drug for pediatric renal transplantation.
- Steroid reduction or discontinuation may be feasible with combination immunosuppression including MZ.
- MZ offers a potentially more beneficial alternative to AZA, particularly in combination with CNI.